CHEN Ning, TANG Jing, LI Jin, et al. Research Status and Hotspots of Treatment for Monoclonal Antibody Drugs. [J]. (1):116-119(2023)
DOI:
CHEN Ning, TANG Jing, LI Jin, et al. Research Status and Hotspots of Treatment for Monoclonal Antibody Drugs. [J]. (1):116-119(2023) DOI: 10.14009/j.issn.1672-2124.2023.01.024.
Research Status and Hotspots of Treatment for Monoclonal Antibody Drugs
OBJECTIVE: To investigate the research hotspots of monoclonal antibody drugs at home and abroad
and to analyze possible research trends. METHODS: Using the publicly available literature of monoclonal antibody drug research on CNKI and PubMed as basic data(retrieval time: Jan. 1982 to Jan. 2022)
the two document databases were analyzed by using the CiteSpace tool
so as to derive the hotspots and differences of domestic and foreign research. RESULTS: The knowledge map analysis of literature in the two databases showed that breast cancer
antibody-conjugates drugs
clinical trials and targeted therapy are the hotspots of domestic and foreign literature research. CONCLUSIONS: The literature study of CiteSpace suggests that the research of monoclonal antibody drugs is in a period of substantial enhancement
which shows unique advantages and prospects in the fields of oncology
autoimmunity
metabolism and other diseases; China ranks 4th in the world in terms of the number of publications related to monoclonal antibody drug research
and occupies an important position in this research.